Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i in Advanced Lung Cancer with Diabetes
NCT07272057Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
Trial of dapagliflozin in lung cancer (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Number of Participants with death at 12 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT07272057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272057.